TY - JOUR
T1 - Effect of a glucagon receptor antibody (REMD-477) in type 1 diabetes
T2 - A randomized controlled trial
AU - Pettus, Jeremy
AU - Reeds, Dominic
AU - Cavaiola, Tricia S.
AU - Boeder, Schafer
AU - Levin, Michelle
AU - Tobin, Garry
AU - Cava, Edda
AU - Thai, Dung
AU - Shi, Jim
AU - Yan, Hai
AU - Bautista, Edgar
AU - McMillan, John
AU - Unger, Roger
AU - Henry, Robert R.
AU - Klein, Samuel
N1 - Publisher Copyright:
© 2017 John Wiley & Sons Ltd
PY - 2018/5
Y1 - 2018/5
N2 - The aim of the current study (Clinical trial reg. no. NCT02715193, clinicaltrials.gov) was to study the efficacy and safety of REMD-477, a glucagon receptor antagonist, in type 1 diabetes. This was a randomized controlled trial in which 21 patients with type 1 diabetes were enrolled. Glycaemic control and insulin use were evaluated in outpatient and inpatient settings, before and after a single 70-mg dose of REMD-477 (half-life 7-10 days) or placebo. Inpatient insulin use was 26% (95% CI, 47%, 4%) lower 1 day after dosing with REMD-477 than with placebo (P =.02). Continuous glucose monitoring during post-treatment days 6 to 12 showed that average daily glucose was 27 mg/dL lower (P <.001), percent time-in-target-range (70-180 mg/dL) was ~25% greater (~3.5 h/d) (P =.001), and percent time-in-hyperglycaemic-range (> 180 mg/dL) was ~40% lower (~4 h/d) (P =.001) in the REMD-477 group than in the placebo group, without a difference in percent time-in-hypoglycaemic-range (<70 mg/dL). No serious adverse events were reported. Glucagon receptor antagonism decreases insulin requirements and improves glycaemic control in patients with type 1 diabetes.
AB - The aim of the current study (Clinical trial reg. no. NCT02715193, clinicaltrials.gov) was to study the efficacy and safety of REMD-477, a glucagon receptor antagonist, in type 1 diabetes. This was a randomized controlled trial in which 21 patients with type 1 diabetes were enrolled. Glycaemic control and insulin use were evaluated in outpatient and inpatient settings, before and after a single 70-mg dose of REMD-477 (half-life 7-10 days) or placebo. Inpatient insulin use was 26% (95% CI, 47%, 4%) lower 1 day after dosing with REMD-477 than with placebo (P =.02). Continuous glucose monitoring during post-treatment days 6 to 12 showed that average daily glucose was 27 mg/dL lower (P <.001), percent time-in-target-range (70-180 mg/dL) was ~25% greater (~3.5 h/d) (P =.001), and percent time-in-hyperglycaemic-range (> 180 mg/dL) was ~40% lower (~4 h/d) (P =.001) in the REMD-477 group than in the placebo group, without a difference in percent time-in-hypoglycaemic-range (<70 mg/dL). No serious adverse events were reported. Glucagon receptor antagonism decreases insulin requirements and improves glycaemic control in patients with type 1 diabetes.
KW - diabetes
KW - glucose homeostasis
KW - glycaemic control, insulin
UR - http://www.scopus.com/inward/record.url?scp=85045318550&partnerID=8YFLogxK
U2 - 10.1111/dom.13202
DO - 10.1111/dom.13202
M3 - Article
C2 - 29283470
AN - SCOPUS:85045318550
SN - 1462-8902
VL - 20
SP - 1302
EP - 1305
JO - Diabetes, Obesity and Metabolism
JF - Diabetes, Obesity and Metabolism
IS - 5
ER -